Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.

"Conflict of interest SJH reports a consultancy/advisory role for AbbVie, Amgen, Celgene, GSK, Janssen, Novartis, Roche/Genentech, Sanofi and Takeda; honoraria from Amgen, Celgene, Janssen, Novartis, Roche/Genentech and Takeda; study investigator for AbbVie, Amgen, Celgene, Janssen, Novartis, Roche/Genentech and Haemalogiz; and research funding from Amgen, Celgene, GSK, Janssen, Novartis and Haemalogix. AP reports honoraria/congress support from Amgen, Celgene, Janssen, Sanofi; and reports grant support from Takeda. AA reports honoraria from Amgen, Celgene, Janssen, Sanofi and Takeda; membership on an entity’s Board of Directors or advisory committees at Amgen, Celgene, Janssen, Sanofi and Takeda. DS reports honoraria from AbbVie, Janssen, Roche; employment, stock and research funding from Beigene; research funding from Amgen, Celgene and Merch Shape Dohme, Acerta, Pharmacyclics, Sanofi and GSK. MCW has no disclosures. AS reports a consultancy role for Secura Bio, Celgene, Takeda, Janssen, Specialised Therapeutics Australia, AbbVie, Servier, Haemalogix and Sanofi; honoraria from Secure Bio, Celgene, Takeda, Janssen, Specialised Therapeutics Australie, AbbVie, Servier, Haemalogix, Sanofi and Amgen; personal fees associated with the Speaker’s Bureau for Celgene, Takeda and Janssen. SD reports personal fees associated with the Speaker’s Bureau for Amgen and Janssen. CH reports personal fees from Sanofi, Janssen and Celgene. TF reports data monitoring board participation for Sanofi; advisory board role for Celgene, Janssen, Takeda, Roche, Oncopeptides, Karyopharm, Amgen. PV reports advisory board and travel support from Celgene and Takeda, and travel support from Amgen. KY reports a consultancy/advisory role with Amgen, Janssen and Takeda; is in the Speaker’s bureau for Amgen and Takeda; received research funding from Amgen and Sanofi. FC, MI, SM, MLR, HvdV are employees of Sanofi and may hold shares and/or stock options in the company."

"The ICARIA‐MM study was sponsored by Sanofi. The authors thank the participating patients and their families, and the study centres and investigators, for their contributions to the study. We thank Solenn Le Guennec for her contributions to the statistical analysis. Medical writing support was provided by Stephanie Brillhart and Smitha Reddy of Elevate Medical Affairs (Fairfield, CT, USA), and funded by Sanofi (Cambridge, MA, USA)."

"The ICARIA‐MM study has been previously described,, and is registered at ClinicalTrials.gov, number NCT02990338. Briefly, eligible patients had RRMM and received ≥2 prior lines of therapy and were refractory to lenalidomide and a proteasome inhibitor given alone or in combination. The protocol was approved by independent ethics committees and institutional review boards at all participating institutions. All authors had full access to the study data. Written informed consent was obtained from all patients."